Lazard Asset Management LLC Chemo Centryx, Inc. Transaction History

Lazard Asset Management LLC

$68.3 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $26,470 - $61,849	1,194 New	1,194 $61,000
Q1 2022 May 13, 2022	SELL	$22.22 - $39.12 $36,729 - $64,665	-1,653 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$18.38 - $40.5 $30,382 - $66,946	1,653 New	1,653 $60,000
Q4 2020 Feb 11, 2021	SELL	$47.25 - $65.16 $6,851 - $9,448	-145 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $6,720 - $8,945	145 New	145 $7,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.